whether neoadjuvant chemotherapy was administered with trastuzumab alone or with an additional HER2-targeted agent, pathological nodal status at surgery, age cohorts, and race. However ...

In large, multicenter trials of trastuzumab as a single agent or in combination with chemotherapy as first-line or second-line therapy for metastatic breast cancer (MBC), response rates have ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

In the UK, intravenous trastuzumab is used mainly as part of the combination with Perjeta and chemotherapy in breast cancer, and in metastatic gastric cancer. It will be in these indications where ...

In the almost 30-years since the protests at the Genentech headquarters, HER2+ breast cancer treatments that include Herceptin® - such as chemotherapy with the addition of Herceptin® or ...